s-1-(combination) and Pancytopenia

The aim of this study was to assess the feasibility of using S-1 as adjuvant chemotherapy after the resection of pancreatic cancer.. S-1 was initially administered or ally at a dose of 50 mg twice daily for 14 days, followed by a rest period of seven days to complete one course. Administration was repeated with dose escalation in each cycle until the recommended dose (RD; 80 mg/m2, maximum 120 mg/day), unless grade 3 adverse events were observed. Administration was planned to continue at least 6 months (eight courses).. Eighteen patients who had undergone resection of pancreatic adenocarcinoma were enrolled in this study. The RD could be administered to 12 patients(67%), and 80% of the RD was given to five patients(28%). Although grade 3 anemia occurred in one patient, grade 4 hematologic adverse events were not observed. Grade 3 cutaneous toxicity (hand-foot syndrome)was observed in two patients. The cumulative relative total administered dose rate of S-1 was 0. 86. The 3-year relapse-free survival rate was 31. 4%, and the median overall survival time was 25. 3 months.. Long-term postoperative administration of S-1 at the RD is safe and appears to be a promising method of adjuvant chemotherapy.

Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancytopenia; Survival Rate; Tegafur

The patient was a 74-year-old woman with gastric cancer with multiple liver metastasis. She was treated with daily oral administration of TS-1 100 mg/day (day 1-21) and systemic administration of CDDP 90 mg (day 8) as neoadjuvant chemotherapy for 2 courses. As metastatic lesions became smaller, we performed distal gastrectomy. TS-1 was started for the residual cancer lesion. However, liver metastatic lesions increased in size, so we carried out intraarterial chemotherapy (IAC), Nausea appeared at 9 days, pancytopenia at 28 days and ARDS at 78 days after IAC. She died due to ARDS.

Topics: Aged; Antimetabolites, Antineoplastic; Cisplatin; Drug Combinations; Female; Fluorouracil; Gastrectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Oxonic Acid; Pancytopenia; Pyridines; Respiratory Distress Syndrome; Stomach Neoplasms; Tegafur